Medications

Drug boosts survival for women with advanced ovarian cancer

Women with advanced ovarian cancer often face grim statistics, with less than half surviving for five years after their diagnosis. However, a new study suggests that so-called "maintenance therapy" with a targeted cancer ...

Medical research

NICE approves new maintenance treatment for ovarian cancer

A new targeted treatment has been recommended by the National Institute of Health and Care Excellence (NICE) for some adults with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer

Oncology & Cancer

Scientists take early step to personalized breast cancer care

UT Southwestern Medical Center researchers have developed a method to map protein changes that occur in different subtypes of breast cancer cells in response to DNA damage from a new class of chemotherapy drugs.

Oncology & Cancer

Rucaparib—targeting DNA repair and a patient's perpective

Inhibitors of the DNA repair enzyme poly (ADP-ribose) polymerase (PARP) kill BRCA-deficient tumours, and have significant activity in single agent and combination therapy. Professor Herbie Newell, of Newcastle University ...

Oncology & Cancer

Sister cells uncover pre-existing resistant states in cancer

In many cancers, such as ovarian cancer, each round of chemotherapy kills the majority of cancer cells, while a small population of them survives through treatment. These cells are typically more resistant for the next cycle ...

page 8 from 11